IDEXX Laboratories (IDXX) 10-K Summary — Year Ended Dec 31, 2023
The filing indicates revenue growth and positive operating cash flow for the company. The supplied context does not contain detailed business descriptions or specific risk factors.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
The filing indicates revenue growth and positive operating cash flow for the company. The supplied context does not contain detailed business descriptions or specific risk factors.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$3.7B
Revenue reported for the fiscal year.
Operating income
$1.1B
Income from operations reported for the year.
Net income
$845M
Net income reported for the year.
Operating cash flow
$906.5M
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $3.2B | n/a |
| Dec 31, 2022 | $3.4B | +4.7% |
| Dec 31, 2023 | $3.7B | +8.7% |
Business overview
The filing references a business overview section but does not provide any descriptive text about the company's operations within the supplied context.
Financial performance
Revenue increased from the prior year, and operating income and net income were reported at levels consistent with the company's profitability. Operating cash flow was also positive.
Material risks
The filing references risk factors but does not include specific risk descriptions in the supplied context.
Liquidity and capital
The filing reports operating cash flow but does not discuss capital allocation themes or liquidity strategies.
What to watch
Monitor whether the revenue growth trend continues in the next filing.